PRESS RELEASE: MediGene Raises € 15,6 Million in Private Placement with Santo Holding GmbH

MediGene Raises € 15,6 Million in Private Placement with Santo Holding GmbH

Martinsried/Munich, Germany – September 10, 2007. The biotechnology company MediGene announces that Santo Holding (Germany) GmbH will invest in MediGene AG. As representative of Santo Holding (Deutschland) GmbH,Dr. Thomas Strüngmann is personally prepared to join MediGene´s supervisory board. The company will receive approximately 15.6 million € in the course of a private placement from Santo Holding (Germany) GmbH. MediGene placed 3.084.282 new shares from authorized capital. The transaction was resolved today by the management board with the approval of the supervisory board at a price of 5,05 € per share and MediGene thereby increases the registered share capital from 30,842,839.00 € to 33,927,121.00 € . After completion of the transaction, the shares subscribed to by Santo Holding (Deutschland) GmbH will amount to 9.09 % of the total share capital of MediGene AG after completion of the capital increase thus making Santo Holding (Germany) GmbH the largest investor in the company. Dr. Thomas Strüngmann shall become successor of Dr. Manfred Scholz, who has retired from MediGene´s Supervisory Board with effect as of December 31, 2007 due to medical reasons.

Dr. Peter Heinrich, Chief Executive Officer of MediGene AG, said: “We are delighted to welcome one of the most successful pharmaceutical entrepreneurs to MediGene. As cofounder and former member of the management board of the pharmaceutical group Hexal, Dr. Strüngmann has an excellent understanding of and experience in our industry. His expertise and financial dedication will help MediGene to advance in developing and marketing further innovative drugs to achieve our goal of becoming a leading global biotechnology companies.”

Dr. Thomas Strüngmann said: “Biotechnology is a very interesting cutting edge industry. MediGene AG is well positioned and has significant potential in this arena. It is a challenge for me to actively contribute to the future development of this company.”

This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgment of MediGene as of the date of this release. These forwardlooking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forwardlooking statements. MediGeneTM is a trademark of MediGene AG.

- end -

MediGene AG is a publicly quoted biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company with a drug on the market. Another drug obtained marketing authorization for the USA, two drug candidates are currently undergoing the European approval procedures. Furthermore, MediGene has several drug candidates for the treatment of various types of cancer and autoimmune diseases in clinical development, and possesses innovative platform technologies for drug development.

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.